Becton Dickinson gets FDA approval for third drug in its BD Simplist line

|By:, SA News Editor

Becton, Dickinson (BDX +0.3%) subsidiary BD Rx says the FDA has approved a third drug to be offered in its new BD Simplist line of ready-to-administer prefilled generic injectables.

The third product to launch is Ondansetron Injection, an injectable antiemetic which is used to prevent postoperative nausea and vomiting.

The drug is currently on the FDA drug shortage list due to recent demand increases and supply issues faced by other manufacturers.